Tango Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Its last 7 Sell calls were followed by a 12% average decline over the next quarter.
- Recent price momentum is +68.3% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 28.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -178.4% | Better than 6% |
| Net margin | -162.9% | Better than 6% |
| Return on equity | -37.2% | Better than 11% |
| Return on invested capital | -34.8% | Better than 9% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -9.0% | Better than 53% |
| 6-month return | 7.4% | Better than 68% |
| 12-month return (ex latest month) | 178.5% | Better than 99% |
| Distance below 52-week high | 36.8% | Better than 32% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 16.3x | Better than 97% |
| Debt to assets | 8.4% | Better than 73% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 124.0% | Better than 87% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 22.71
- Open
- 22.11
- Day range
- 21.63 - 23.05
- Avg price
- 21.98
- Volume
- 1.74M
- Turnover
- 38.26M
- Turnover ratei
- 1.22%
- Volume ratioi
- 0.80
- Amplitudei
- 6.25%
- 52-week rangei
- 8.30 - 34.39
Valuation
- P/Ei
- -24.98
- P/E (TTM)i
- -15.75
- P/Bi
- 3.76
- EPSi
- -0.87
- Book value / shi
- 5.78
- Net profit
- -147.43M
- Net assets
- 980.13M
Share structure
- Market cap
- 3.68B
- Float capi
- 3.11B
- Shares out
- 169.46M
- Float sharesi
- 143.08M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
36.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+34.66M net over the window
Short interest
- Shares short
- 48.24M
- % of floati
- 28.61%
- Days to coveri
- 9.73
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Tango Therapeutics (TNGX)?
Tango Therapeutics last traded at 21.73. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Tango Therapeutics's market cap?
About 3.68B.
What is the P/E ratio of Tango Therapeutics?
The trailing twelve-month P/E is -15.75. The Valuation tab shows it against the stock's own five-year range.
Does Tango Therapeutics pay a dividend?
Tango Therapeutics does not currently pay a regular dividend.
Is Tango Therapeutics a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 48.67, which implies 124.0% upside from the current price. This is not investment advice.
What is Tango Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Tango Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:41:45 · For reference only, not investment advice and not tailored to your situation.
Tango Therapeutics discussion 0 comments